Ipsen SA, of Paris, said the International Breast Cancer Study Group presented results of the randomized phase III SOFT trial, which assessed the value of ovarian suppression in reducing breast cancer recurrence in young women receiving tamoxifen, and evaluated the role of aromatase inhibitor exemestane plus ovarian suppression in that population.